Bridge to Life CEO Don Webber Shares HOPE Breakthrough with Transplant Community at WTC 2025
First-Ever Multicenter Study of Hypothermic Oxygenated Perfusion (HOPE) with VitaSmart™ in Pediatric Liver Transplants Confirms Safety and Favorable Outcomes
New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation
First-Ever Comparative Study of Hypothermic Oxygenated Machine Perfusion (HOPE) with Normothermic Machine Perfusion (NMP) in Liver Transplantation Shows Better Outcomes With HOPE
Bridge to Life Announces Abstract Presentations at The 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore, May 28-31, 2025
Bridge to Life Ltd. Achieves Global Milestone in Liver Transplants Using Hypothermic Oxygenated Perfusion (HOPE) and VitaSmart™ System